Overview

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Status:
Unknown status

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

This is an open Label, Phase I/II, multicenter study. In the first phase it defines the maximum tolerated dose (MTD) of Bendamustine (B) given in combination with Lenalidomide (L) and low-dose Dexamethasone (d) and in the second phase it evaluates the antitumour activity of Bendamustine, Lenalidomide and Low-dose Dexamethasone (BdL) given in combination, in relapsed multiple myeloma patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Gruppo Italiano Studio Linfomi

Treatments:

BB 1101
Bendamustine Hydrochloride
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide